- US-listed companies
- Crinetics Pharmaceuticals, Inc.
- Income statement
Crinetics Pharmaceuticals, Inc. (CRNX) Income statement
Market cap
$7.9B
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 2 | 1 | 0 | 1 | - | - | 1 |
| Revenue growth (%) | - | - | - | - | |||
| Research & development | 24 | 42 | 57 | 84 | - | - | 240 |
| Operating margin (%) | - | - | |||||
| Operating expenses | 31 | 55 | 75 | 109 | - | - | 340 |
| Operating income | -29 | -54 | -75 | -108 | - | - | -339 |
| Net income | -27 | -50 | -74 | -108 | -164 | -215 | -298 |
| Net income margin (%) | - | - | |||||
| Earnings per share | - | - | - | - | - | - | -3.69 |
| Diluted EPS | - | - | - | - | - | - | -3.69 |